Rwanda has come closer to becoming the first nation to use a World Trade Organization procedure designed to allow developing countries to import cut-price copies of patented drugs, when the Canadian Intellectual Property Office issued a compulsory license authorizing the generic production of a patented HIV/AIDS drug for export to the central African country, the International Center for Trade and Sustainable Development reports on its web site (www.ictsd.org).
Richard Elliott, executive director of the Canadian HIV/AIDS Legal Network, said: "this is [a] big step forward in finally getting at least one affordable medicine from Canada to a developing country in need." However, the fact that this is the first such move in the three years since Canada introduced a legal system for making such exports possible demonstrates the need to simplify the process to make it more efficient and effective, he argued.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze